Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence

Patients who receive antithrombotic therapy as secondary prevention in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) have a better prognosis compared with patients who do not receive antithrombotic treatment [1]. In the VISTA registry the incidence of stroke recurrence, symptomatic intracranial bleeding, all-cause mortality and 90-day modified Rankin Scale (mRS) ≥4 in patients with NVAF-related AIS not receiving antithrombotic treatment was 19.8%, 9.3%, 40.7% and 65.3%, respectively compared with patients receiving vitamin K antagonists (VKAs) (10.6%, 2.9%, 25.5% and 46.6%, respectively) or VKAs plus antiplatelets (6.7%, 1.9%, 17.8% and 54.5%, respectivel y) [1].
Source: Thrombosis Research - Category: Hematology Authors: Tags: Letter to the Editors-in-Chief Source Type: research